It gives clues on the mechanisms on how JAK2 inhibition may modulate platelet counts, block marrow fibrosis and osteosclerosis and prevent mobilization of early neoplastic cells in extramedullary sites decreasing splenomegaly. The gene discussed is JAK2; the disease is Splenomegaly.